Harrow Eye Patent-Cliff Exposure & CMS Drug Spending Portfolio

Harrow Eye (US): 16 reconciled FDA prescription therapies (19.5% 2025 to 2030 cliff risk), $53.2M 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies16
2025 to 2030 Patent-Cliff Revenue Exposure19.5%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$53.2M
2024 Medicare Part D Spend$43.8M
2024 Medicaid Spend$9.4M
California HCAI SB 17 Filings7 WAC filings (max 527.6% 2-yr change)